ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall St set for lower open as Middle East clashes revive rate-hike speculation
- The Warsh pivot markets didn't expect
- Oil rises over 3% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Manhunt underway after woman killed, several injured at Swiss rave shooting
- Aon close to acquiring USI Insurance from KKR in $17 billion deal, WSJ reports
- RedHill sells Talicia to Apotex for $18M upfront plus milestones
Cantor Fitzgerald on ORIC Pharmaceuticals (ORIC): 'Solid Update in Prostate Cancer for ORIC-944'
May 29, 2025 6:20 AM EDTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on ORIC Pharmaceuticals (NASDAQ: ORIC)
The analyst comments "ORIC announced positive P1 data for ORIC-944 (oral PRC2 inhibitor) in prostate cancer. Confirmed PSA50 responses are tracking at ~50% in now a larger sample and starting to look differentiated compared to Pfizers... More
